ABSTRACT Antibodies to the insulin receptor were prepared in BALB/c mice by immunization with IM-9 human lymphocytes, a cell type that has a large number of plasma membrane insulin receptors. The spleens ofthese mice-were then removed, and their lymphocytes were fused to a mouse myeloma cell line, FO cells. After screening over 1,200 resulting hybrids, one stable hybrid was obtained that produced IgGI antibodies directed towards the insulin receptor. This antibody blocked 1251-labeled insulin binding to its receptor by more than 90% in three human tissues: IM-9 cultured lymphocytes, freshly isolated adipocytes, and placenta membranes. In contrast, the antibody did not inhibit insulin binding to rat adipocytes and rat liver plasma membranes, suggesting that the antibody was species specific. In IM-9 cells, which had their proteins prelabeled with [PS]methionine, the antibody precipitated two polypeptides with molecular weights of 135,000 and 95,O00; these molecular weights are identical to those previously identified as the a and fi subunits of the insulin receptor. The monoclonal antibody inhibited the actions of insulin on both human adipocytes and fibroblasts, suggesting that the antibody was an antagonist ofinsulin action. The present studies suggest, therefore, that monoclonal antibodies to the insulin receptor may provide new insights into the structure of the insulin receptor and its interaction with insulin.
Antibodies to the insulin receptor occur in rare patients with insulin resistance and acanthosis nigricans (1) (2) (3) . These antibodies, which are polyclonal in nature, both inhibit insulin binding and mimic many of the actions of insulin (3) (4) (5) . For these reasons, the antibodies are an important tool for both purifying the insulin receptor (6) and studying the actions of insulin (7) .-Because the availability of these antibodies is limited, attempts, have been made to prepare similar blocking antibodies in laboratory animals by using purified preparations of insulin receptor as immunogens (8, 9) . These efforts have been only partially successful because the antibodies obtained bind to the insulin receptor but fail to inhibit insulin binding (8, 9 ). Recently we have described a method for producing antibodies that block the binding of insulin to the human insulin receptor (10) . In this method, mice are immunized with intact IM-9 human lymphocytes, acell line with a large number ofcell-surface insulin receptors (11) . In the present study, we took the spleens of mice immunized by this protocol, fused their lymphocytes to the FO myeloma cell line, and identified a hybridoma producing antibodies to the insulin receptor. The characteristics ofthis monoclonal anti-insulin receptor antibody are the subject of this report.
MATERIALS AND METHODS
Production of Monoclonal Antibodies. Female BALB/c mice (6-8 wk old; Simonsen Laboratories, Gilroy, CA) were immunized by injection of 106 IM-9 cells into the peritoneum as described (10) . One month later, the mice were reinjected by the same protocol; 3 days after this injection, their splenic lymphocytes were fused to FO cells by the addition of 50% polyethylene glycol 4000 GF (Merck, Darmdstadt, Federal Republic of Germany) as detailed by de St. Groth and Scheidegger (12) . When the hybrid cells were semiconfluent, their supernatants were tested for their ability to inhibit the binding of'"I-labeled insulin ('"I-insulin) to IM-9 cells as described below. Positive hybrids (those inhibiting binding by more than 70%) were cloned by limiting dilution (13) . The monoclonal antibodies from the supernatants of the cells were purified on protein A-Sepharose (Pharmacia) (13) , and their heavy and light chains were identified by the use of specific antisera (Miles) in Ouchterlony two-dimensional immunodiffusion.
Inhibition of 1251-Insulin Binding and Biological Studies. IM-9 cells. Routine screening of the sera and hybridoma supernatants was performed as described (10) . For the final characterization of the monoclonal antibodies, the method was modified as follows. IM-9 cells (5 x 105) in a final volume of 0.5 ml of minimal Eagle's medium (without bicarbonate) containing 20 mM Hepes (pH 7.6) and 1% bovine serum albumin were incubatedfor 30 min at 15'C with either the antibody or unlabeled insulin. Then, 100 pM 125I-insulin (130 Ci/g; 1 Ci = 3.7 x 1010 becquerels) was added, and the incubation was continued for 70 min at 15°C. Tubes were then chilled to 40C and centrifuged for 10 min at 800 x g, and the pellets were washed twice with 154 mM NaCl at 40C and counted.
Adipocytes. Isolated adipocytes were prepared from either rat epididymal fat pads or subcutaneous human adipose tissue by the method ofRodbell by digesting 1 g of tissue for 40 min at 370C with 5 mg of collagenase (Worthington) in 2.5 ml of Krebs-Ringer bicarbonate buffer (14) . Isolated (18) . The material from this column was absorbed with monoclonal antibody bound to Staphylococcus aureus (New England Enzyme Center, Boston, MA) through an affinity-purified rabbit antimouse Ig bridge. The immunoprecipitated proteins were electrophoresed on a 7.5% polyacrylamide gel (19) , and the gels were processed and the molecular weights were calculated as described (18) .
RESULTS
Screening of Hybridomas. Spleen cells of BALB/c mice immunized with whole IM-9 cells were fused with FO cells, a nonsecreting murine myeloma (12 
nM).
The direct binding of this monoclonal antibody to IM-9 lymphocytes was also studied after labeling the antibody with '"I as has been described for polyclonal antibody to the insulin receptor (2) . In agreement with the observation that the anti-receptor IgG had less potency than insulin in inhibiting 12'I-insulin binding, the 125I-anti-receptor IgG bound less strongly than l25I-insulin to IM-9 cells. The binding of the labeled antibody to these cells was inhibited by unlabeled insulin; maximal inhibition was 95% and one-half maximal inhibition occurred at 0.4 nM insulin (Fig. 1 Lower) . In contrast to unlabeled insulin, the effect of unlabeled anti-receptor IgG on the binding of the labeled monoclonal antibody was biphasic. At concen- trations below 1 nM, the antibody caused a small stimulation of binding, an effect that may have been due to either positive cooperativity (20) or up-regulation of the receptor (21) . At concentrations greater than 1 nM, the anti-receptor IgG inhibited binding by more than 90% with a one-half maximal effect occurring at 2 nM.
These results suggested, therefore, that the monoclonal antibody was directed against the insulin receptor. To further study the specificity ofthe monoclonal antibody, extracts of IM-9 cells labeled with [35S]methionine were absorbed with the monoclonal antibody. The labeled proteins bound were then released with mercaptoethanol and NaDodSO4 and analyzed by polyacrylamide gel electrophoresis. The monoclonal antibody was found to precipitate specifically two major polypeptides of apparent Mrs 135,000 and 95,000 (Fig. 2, lane A) . These polypeptides were not present when normal IgG was used for the precipitation (Fig. 2, lane C) . In addition, the precipitation of these polypeptides by the monoclonal antibody was inhibited by the addition of insulin (Fig. 2, lane B) .
Studies with Adipocytes. The monoclonal antibody was then tested for its ability to inhibit the binding of 1251-insulin to freshly prepared human adipocytes. Unlabeled insulin inhibited binding with a one-halfmaximal effect occurring at 0.2 nM. The monoclonal anti-receptor IgG was found to inhibit this binding with one-half maximal inhibition occurring at 10 nM (Fig. 3 Upper) . Therefore, the potency of the monoclonal antibody in blocking binding to this tissue was 1/50 that of native insulin. In contrast, normal IgG did not inhibit 1251-insulin binding.
The biological activity of the monoclonal anti-receptor IgG was then studied in the human adipocytes. In this cell type, the Cell Biology: Roth et antibody stimulated 2-deoxyglucose uptake by 20% at 100 nM; however, a similar effect was seen with normal IgG (Fig. 3 Lower). Most likely, therefore, this small stimulation of 2-deoxyglucose uptake reflected the known insulin-like effects of IgG on adipocytes (22) . We then examined the ability ofthe antireceptor IgG to inhibit the effect of insulin on 2-deoxyglucose uptake in these cells. Anti-receptor IgG at 20 nM inhibited maximal insulin stimulation of 2-deoxyglucose uptake by 60%. In contrast, normal IgG at 20 nM did not inhibit the response of these cells to insulin.
In contrast to these results with human adipocytes, in rat adipocytes the monoclonal antibody did not block binding of 125I-insulin at concentrations up to 100 nM (Fig. 4 Upper). In addition, the monoclonal antibody neither had insulin-like effects on these cells nor blocked the action of insulin on these cells (Fig. 4 Lower).
Studies with Human Fibroblasts. Human fibroblasts have been shown to respond to insulin and its analogues with an increase in amino acid uptake (16) . In order to determine whether the monoclonal antibody would antagonize.the action of insulin in another cell type, human fibroblasts were preincubated with either 300 nM anti-receptor IgG, 300 nM normal IgG, or buffer and then were incubated with various concentrations of insulin (Fig. 5) . At all the insulin concentrations tested, the monoclonal anti-receptor IgG inhibited insulin stimulation by 60%. In contrast, normal IgG had no effect on the response of the cells to insulin. When 300 nM anti-receptor IgG and 300 nM normal IgG were tested for their ability to effect the uptake of amino-
[3H]isobutyric acid in the absence of insulin, neither stimulation nor inhibition was observed (Fig. 5) lines of evidence indicate that this antibody is directed against the insulin receptor. First, the antibody blocked the binding of 1251-insulin to three human tissues, IM-9 cultured lymphocytes, freshly isolated adipocytes, and placenta membranes (unpublished studies). Second, in IM-9 cultured lymphocytes, the binding of labeled antibody was inhibited by unlabeled insulin. Third, when the proteins of the IM-9 lymphocyte were labeled with [3`S] methionine, the antibody specifically precipitated two polypeptides with Mrs of 135,000 and 95,000, values identical to those previously identified as the a and /3 subunits, respectively, of the insulin receptor (23, 24) . Moreover, this precipitation was inhibited when unlabeled insulin was present. And fourth, although the antibody itself had no insulin-agonist activity, when adipocytes or fibroblasts were preincubated with the antibody, the biological activity of insulin was inhibited. One unique characteristic of this antibody was that it inhibited insulin binding to the human.insulin receptor but not to the rat receptor. Prior studies with the polyclonal antibodies from patients with insulin resistance have indicated that these antibodies readily crossreact with insulin receptors from a wide variety of species (1) . In contrast, the monoclonal antibody did not block the insulin binding to either rat liver plasma membranes (unpublished studies) or isolated rat adipocytes. In addition, the monoclonal antibody had no biological effects on rat adipocytes. Thus, although there is biochemical and immunological evidence that the structure of the insulin receptor is highly conserved (25) , the present study suggests that there are 7314 Cell Biology: Roth et al. ing of 125I-insulin to its receptor. However, like the present antibody, this antibody recognized the human insulin receptor but not the rat insulin receptor. Moreover, this monoclonal antibody also showed tissue specificity in that it was more reactive with the insulin receptor from placenta than with the 100 -_ g~~~~~~~~~~~receptor from erythrocytes.
Recent studies have shown that the receptor for the insulinlike growth factor designated IGF-I is similar in structure to the ,^8 0 insulin receptor (27, 28) . Our studies as a component of the insulin receptor (30, 33, 34, 36) .
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Because these prior immunoprecipitation studies utilized polyclonal antibodies that also could contain antibodies to other proteins (18) , it was possible that the Mr 95,000 component was not bound by antibodies to the insulin receptor and, hence, was not a true constituent ofthe insulin receptor. Thus, in the present study, in which we utilize immunoprecipitation with a monoclonal antibody, the finding that the Mr 135,000 and Mr 95,000 components are present in comparable amounts supports the concept that the Mr 95,000 polypeptide is a real constituent ofthe insulin receptor. In addition, the absence ofa Mr 50,000 component indicates that this component is not an integral part of the insulin receptor of the IM-9 cell. In summary, we have isolated a hybridoma that produces antibodies to the insulin receptor. Because these antibodies block the binding ofinsulin to the receptor, they are most likely directed to a site on the receptor near the insulin binding site, although it is also possible that the antibodies induce a conformational change in the receptor that decreases insulin binding. In either case, these antibodies provide a useful tool for further studies on the structure of the insulin receptor and a probe of the relationship between hormone binding and the elicitation of a biological response.
